



References

1. Houssami N, Ciatto S, Turner RM, Cody HS, 3rd, Macaskill P. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. *Annals of surgery*. Aug 2011;254(2):243-251.
2. Heusner TA, Kuemmel S, Hahn S, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. *European journal of nuclear medicine and molecular imaging*. Oct 2009;36(10):1543-1550.
3. Koolen BB, Vrancken Peeters MJ, Aukema TS, et al. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. *Breast cancer research and treatment*. Jan 2012;131(1):117-126.
4. Groheux D, Hindie E, Delord M, et al. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. *Journal of the National Cancer Institute*. Dec 19 2012;104(24):1879-1887.
5. Riedl CC, Slobod E, Jochelson M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Oct 2014;55(10):1578-1583.
6. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. *European journal of nuclear medicine and molecular imaging*. Mar 2006;33(3):254-262.
7. Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Oct 10 2008;26(29):4746-4751.
8. Constantinidou A, Martin A, Sharma B, Johnston SR. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. Feb 2011;22(2):307-314.
9. Dashevsky BZ, Goldman DA, Parsons M, et al. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. *European journal of nuclear medicine and molecular imaging*. Oct 2015;42(11):1666-1673.
10. Hogan MP, Goldman DA, Dashevsky B, et al. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Nov 2015;56(11):1674-1680.
11. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Nov 1993;11(11):2101-2111.



12. Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Mar 2002;43(3):325-329.
13. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. *European journal of nuclear medicine and molecular imaging*. Sep 2007;34(9):1339-1347.
14. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *The New England journal of medicine*. Mar 8 2012;366(10):883-892.
15. Huyge V, Garcia C, Alexiou J, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. *Clinical oncology*. Dec 2010;22(10):818-827.
16. Lorincz T, Toth J, Badalian G, Timar J, Szendroi M. HER-2/neu genotype of breast cancer may change in bone metastasis. *Pathology oncology research : POR*. 2006;12(3):149-152.
17. Riedl CC. American Society of Clinical Oncology; 2015; Chicago.
18. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. *Breast cancer research and treatment*. Feb 2009;113(3):509-517.